This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today.
Eli Lilly says an experimental drug slows Alzheimer's worsening
A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.
(
Darron Cummings
/
AP
)
WASHINGTON — Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.
In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.
The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.
A similar amyloid-targeting drug, Eisai and Biogen's Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer's — and also some safety concerns, brain swelling or small brain bleeds.
Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.
The preliminary study results haven't been vetted by outside experts. Indianapolis-based Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking Food and Drug Administration approval of the drug.
Copyright 2023 NPR. To see more, visit https://www.npr.org. 9(MDA1OTI3MjQ5MDEyODUwMTE2MzM1YzNmZA004))
You come to LAist because you want independent reporting and trustworthy local information. Our newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our connected community. We are free to tell the full truth, to hold power to account without fear or favor, and to follow facts wherever they lead. Our only loyalty is to our audiences and our mission: to inform, engage, and strengthen our community.
Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive from readers like you will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.
If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Your tax-deductible donation keeps LAist independent and accessible to everyone.
Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive from readers like you will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.
If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Your tax-deductible donation keeps LAist independent and accessible to everyone.
Senior Vice President News, Editor in Chief
